DS-2325a clinical trials

A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients with Netherton Syndrome

This study is testing a new medicine, DS-2325a, for Netherton Syndrome. It's looking at how safe it is, how the body uses it, and if it shows early signs of helping. Patients will either get the medicine or a placebo (dummy medicine).